statistiche ricercatore

Continente	#
NA - Nord America	585
AS - Asia	382
EU - Europa	332
SA - Sud America	71
AF - Africa	57
Continente sconosciuto - Info sul continente non disponibili	19
OC - Oceania	1
Totale	1.447

Nazione	#
US - Stati Uniti d'America	571
SG - Singapore	124
IT - Italia	73
CN - Cina	72
SE - Svezia	59
VN - Vietnam	59
BR - Brasile	58
GB - Regno Unito	50
HK - Hong Kong	49
DE - Germania	39
FR - Francia	35
CI - Costa d'Avorio	30
BG - Bulgaria	25
IN - India	16
JP - Giappone	15
TR - Turchia	14
RU - Federazione Russa	12
SN - Senegal	11
NG - Nigeria	9
ES - Italia	7
ID - Indonesia	7
IQ - Iraq	7
CA - Canada	6
FI - Finlandia	5
PL - Polonia	4
AR - Argentina	3
BE - Belgio	3
EC - Ecuador	3
SA - Arabia Saudita	3
UA - Ucraina	3
VE - Venezuela	3
AE - Emirati Arabi Uniti	2
AT - Austria	2
BB - Barbados	2
BD - Bangladesh	2
CO - Colombia	2
GR - Grecia	2
IE - Irlanda	2
JO - Giordania	2
KG - Kirghizistan	2
LT - Lituania	2
MX - Messico	2
NL - Olanda	2
PH - Filippine	2
PT - Portogallo	2
SK - Slovacchia (Repubblica Slovacca)	2
TT - Trinidad e Tobago	2
ZA - Sudafrica	2
AO - Angola	1
AU - Australia	1
AZ - Azerbaigian	1
CG - Congo	1
CL - Cile	1
CR - Costa Rica	1
DZ - Algeria	1
EE - Estonia	1
EG - Egitto	1
HR - Croazia	1
IS - Islanda	1
JM - Giamaica	1
KE - Kenya	1
KZ - Kazakistan	1
MO - Macao, regione amministrativa speciale della Cina	1
PE - Perù	1
SY - Repubblica araba siriana	1
TW - Taiwan	1
UZ - Uzbekistan	1
Totale	1.428

Nome	#
Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons	160
Antibiotic Drugs and Unresolved Sensory Side Effects: Analysis of Eudravigilance Database of Suspected Adverse Drug Reaction Reports	159
Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study)	142
Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact	135
Listening Social Media for Pharmacovigilance Objectives: Which Usefulness?	135
Anticoagulant Therapy and Risk of Bleeding in Patients with Atrial Fibrillation of Four Italian Regions: The TYRION Study	134
The Economic Impact of the Introduction of Infliximab-Biosimilar: Preliminary Results from a Study on Rheumatologic Patients in Tuscany, Italy	128
THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES	128
Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease	113
Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments	112
Switching from infliximab-originator to infliximab-biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy	101
Totale	1.447

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	144	0	12	11	2	19	28	7	10	11	1	13	30
2022/2023	269	29	48	16	17	24	24	5	13	66	0	24	3
2023/2024	154	7	9	9	3	24	28	18	12	4	7	23	10
2024/2025	392	3	13	6	33	35	69	16	14	35	58	34	76
2025/2026	410	46	28	27	17	61	26	87	15	38	42	7	16
2026/2027	8	7	1	0	0	0	0	0	0	0	0	0	0
Totale													1.447

CINECA IRIS Institutional Research Information System